Venetoclax: A narrative drug review
Authors:
Open Access
- 1 July 2022
- journal article
- Published by Medknow in Cancer Research, Statistics, and Treatment
- Vol. 5 (3) , 519-532
Abstract
B cell lymphoma 2 (BCL2) is frequently overexpressed in lymphoid and myeloid malignancies. Targeting BCL2 using venetoclax has significantly improved outcomes in patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), resulting in its approval in the first line in both these diseases. Its role in the management of mantle cell lymphoma, multiple myeloma, and diffuse large B cell lymphoma (DLBCL) is also being explored. This review of venetoclax details the pharmacodynamics, pharmacokinetics, clinical indications, dosing strategies, methods to prevent tumor lysis syndrome, and dose modifications. To prepare this review, we comprehensively searched various websites, including that of the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA) drug manual, PubMed, and UpToDate using the search terms, “Venetoclax,” “AML,” “CLL,” “Pharmacology,” and “hematolymphoid malignancy.” We shortlisted all the full-text articles published in the preceding 10 years. Out of a total of 397 manuscripts identified, we included 57. We also incorporated information from the abstracts and various conference proceedings.Keywords
This publication has 52 references indexed in Scilit:
- Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapyHematological Oncology, 2022
- Individualized AML Induction with Venetoclax Based Therapy in Unfit Treatment Naïve Patients Aged ≤ 60 Years: A Real World Perspective from IndiaBlood, 2021
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2020
- A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.Journal of Clinical Oncology, 2020
- Venetoclax: Targeting BCL2 in Hematological Cancers2018
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyThe Lancet Oncology, 2017
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclaxLeukemia, 2015
- Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphomaLeukemia, 2013
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaLeukemia, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013